$RPRX Income Statement | Understand Stock

$RPRX

$65.28 +$0.52 (0.8%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Income and other revenues
Income from financial royalty assets
Revenue from intangible royalty assets
Other royalty income and revenues
Total income and other revenues
Operating (income)/expense
Provision for changes in expected cash flows from financial royalty assets
Provision for credit losses on unfunded commitments
Research and development funding expense
Amortization of intangible assets
General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4)
Other operating expenses
Financial royalty asset impairment
Total operating expense, net

Operating income
Other (income)/expense
Equity in earnings of equity method investees
Interest expense
Losses on derivative financial instruments
Losses/(gains) on equity securities
Gains on available for sale debt securities
Interest income
Other non-operating expenses, net
Total other expense/(income), net
Consolidated net income before tax
Income tax expense
Consolidated net income
Net income attributable to non-controlling interests
Net income attributable to Royalty Pharma plc
Earnings per Class A ordinary share:
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted average Class A ordinary shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments